Entinostat (MS-275)

Catalog No.S1053 Synonyms: SNDX-275

Entinostat (MS-275) Chemical Structure

Molecular Weight(MW): 376.41

Entinostat (MS-275) strongly inhibits HDAC1 and HDAC3 with IC50 of 0.51 μM and 1.7 μM in cell-free assays, compared with HDACs 4, 6, 8, and 10. Phase 3.

Size Price Stock Quantity  
In DMSO USD 91 In stock
USD 70 In stock
USD 150 In stock
USD 270 In stock
USD 770 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 104 Publications

Purity & Quality Control

Choose Selective HDAC Inhibitors

Biological Activity

Description Entinostat (MS-275) strongly inhibits HDAC1 and HDAC3 with IC50 of 0.51 μM and 1.7 μM in cell-free assays, compared with HDACs 4, 6, 8, and 10. Phase 3.
Targets
HDAC1 [2]
(Cell-free assay)
HDAC3 [2]
(Cell-free assay)
0.51 μM 1.7 μM
In vitro

MS-275 shows inhibitory to HDACs by 2'-amino group. MS-275 induces accumulation of p21WAF1/CIP1 and gelsolin in K562 cell. MS-275 could reduce S-phase cells and induce G1-phase cells in A2780 cell. MS-275 inhibits the proliferation of human tumor cell lines including A2780, Calu-3, HL-60, K562, St-4, HT-29, KB-3-1, Capan-1, 4-1St and HCT-15 with IC50 from 41.5 nM to 4.71 μM, which due to HAD-inhibition. [1] MS-275 is not sensitive to other HDACs (4, 6, 8 and 10) with IC50 about/above 100 μM. [2] MS-275 shows great inhibition to human leukemia and lymphoma cells, including U937, HL-60, K562, and Jurkat. MS-275 also decreases expression of cyclin D1 and the antiapoptotic proteins Mcl-1 and XIAP. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
SCC-3 Ml;JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGPwNXBKSzVyPUCuNFYyKM7:TR?= NH\OS|ZUSU6JRWK=
ALL-PO M4TMUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn\pTWM2OD1yLkC2N|U2KM7:TR?= MoSxV2FPT0WU
697 NILEc49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYnJR|UxRTBwMEm5O|Yh|ryP NXTS[2FvW0GQR1XS
NCI-H748 Mm[2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVLOOIp4UUN3ME2wMlExOzN2IN88US=> NET4VXBUSU6JRWK=
NKM-1 M{LQTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{m3V2lEPTB;MD6xNFkyOiEQvF2= NF;TO2dUSU6JRWK=
ES1 M4n5[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mke3TWM2OD1yLkGxNlU2KM7:TR?= MljOV2FPT0WU
NCI-H1963 NVLUbo1xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn33TWM2OD1yLkGxOVc6KM7:TR?= M3zy[HNCVkeHUh?=
NCI-H1417 NW\PbVl4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTBwMUK5O|Qh|ryP MmPFV2FPT0WU
NEC8 NGTN[WhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF3yZYFKSzVyPUCuNVM2OjdizszN Mn65V2FPT0WU
CRO-AP2 NYDSTmtHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlnPTWM2OD1yLkG2PFg6KM7:TR?= MkjkV2FPT0WU
A3-KAW MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHjFUFZKSzVyPUCuNVc3OjdizszN MX7TRW5ITVJ?
SF539 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2TxT2lEPTB;MD6xPVU6OyEQvF2= MVXTRW5ITVJ?
NOS-1 NGLLeYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{X4PWlEPTB;MD6xPVYyQSEQvF2= M{iwcXNCVkeHUh?=
NTERA-S-cl-D1 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX\YTWlpUUN3ME2wMlIxOTF|IN88US=> NVnBVFVQW0GQR1XS
COR-L88 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX:0XHdyUUN3ME2wMlIzQTV7IN88US=> NYHQTHRUW0GQR1XS
EM-2 NH3hOFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmnjTWM2OD1yLkK0NFc6KM7:TR?= NFLWV4hUSU6JRWK=
KARPAS-45 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGi2NnFKSzVyPUCuNlc5OzNizszN Mm[2V2FPT0WU
DSH1 MlvQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUnJR|UxRTBwMki3NFgh|ryP MlnWV2FPT0WU
HT-144 MlPJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF\oRldKSzVyPUCuN|AzPTZizszN MVrTRW5ITVJ?
ATN-1 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3zafWlEPTB;MD6zNFU4PiEQvF2= Mn34V2FPT0WU
HEL M{WxbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlTtTWM2OD1yLkOxN|Q5KM7:TR?= NVvqOppoW0GQR1XS
NB12 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW\JR|UxRTBwM{G3OVYh|ryP MoL5V2FPT0WU
LU-139 NHvQV4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWHJR|UxRTBwM{O1NUDPxE1? NIfoWGJUSU6JRWK=
J-RT3-T3-5 Mn\LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVvJR|UxRTBwM{O3NVYh|ryP NVTDPFYxW0GQR1XS
MOLT-13 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX7JR|UxRTBwM{O4NUDPxE1? MkK3V2FPT0WU
SR M4K5O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4jae2lEPTB;MD6zOFI3OSEQvF2= NG\ze2hUSU6JRWK=
CMK NFWzZ3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUXycYpMUUN3ME2wMlM2PzJ5IN88US=> MX7TRW5ITVJ?
ES8 NFu4UlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{DFTmlEPTB;MD6zOlAzOiEQvF2= MX;TRW5ITVJ?
LB647-SCLC MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEPifGVKSzVyPUCuN|Y4OyEQvF2= MVfTRW5ITVJ?
TE-8 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGTCXlRKSzVyPUCuN|Y6OzVizszN NFTyVJFUSU6JRWK=
BV-173 NWPHUIUxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHn0fJlKSzVyPUCuN|cyOjFizszN NU\DS3FbW0GQR1XS
DEL NWjHeFRWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1nlWGlEPTB;MD6zO|Q5PyEQvF2= M{PhOXNCVkeHUh?=
ARH-77 NWfQ[mF5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWn4cmRZUUN3ME2wMlM5OTl|IN88US=> NUXEbpd4W0GQR1XS
NCCIT M{e4PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFvDUVFKSzVyPUCuN|g3PDlizszN M4nQfXNCVkeHUh?=
RPMI-8402 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXzSWld6UUN3ME2wMlM5PzBzIN88US=> M1X4XHNCVkeHUh?=
MONO-MAC-6 NHmwNo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWDJR|UxRTBwM{i3O|Yh|ryP MV7TRW5ITVJ?
SK-MM-2 NFH0SHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUDJR|UxRTBwM{m4Olgh|ryP NFr4TmVUSU6JRWK=
CHP-126 NHLLRo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVnJR|UxRTBwNECyN|Eh|ryP MoKxV2FPT0WU
A101D MlnSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn62TWM2OD1yLkSwN{DPxE1? NHHZNG9USU6JRWK=
SCH MljyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2\J[GlEPTB;MD60NFM1OiEQvF2= M3TvPHNCVkeHUh?=
NMC-G1 Mly1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYiwT|doUUN3ME2wMlQxOzZ5IN88US=> MnrTV2FPT0WU
NCI-H209 NWDR[pZnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1nQV2lEPTB;MD60NFYyOyEQvF2= MYTTRW5ITVJ?
MOLT-16 M4jOTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1XxWGlEPTB;MD60NVAyPyEQvF2= MWDTRW5ITVJ?
RPMI-6666 NF7wU|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2jrc2lEPTB;MD60NVEzKM7:TR?= NVfOd3NSW0GQR1XS
OPM-2 NVrXbXM1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mlz2TWM2OD1yLkSxOVE{KM7:TR?= NGjUOIFUSU6JRWK=
MRK-nu-1 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2jLVGlEPTB;MD60N|E2OyEQvF2= NYPVbmNiW0GQR1XS
BC-1 M4TOcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXLJR|UxRTBwNEO0NFMh|ryP NYHuRZF5W0GQR1XS
MHH-NB-11 NGD0W3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGfFUldKSzVyPUCuOFM1PTNizszN NWPwXXBGW0GQR1XS
Ramos-2G6-4C10 NX;E[JJIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXrJR|UxRTBwNEO4PVch|ryP NUXHXmxXW0GQR1XS
LS-513 NHTxNVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYfxRlhHUUN3ME2wMlQ1PTBzIN88US=> M4fORnNCVkeHUh?=
K5 NWe1WHdOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHq4Z5pKSzVyPUCuOFcxOjVizszN MXHTRW5ITVJ?
HOP-62 NFvZT|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUPQbFNzUUN3ME2wMlQ5OzV6IN88US=> Mn:xV2FPT0WU
NCI-H187 M3HMT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXnV[IlYUUN3ME2wMlQ6OjJ5IN88US=> NF;CWnVUSU6JRWK=
BE-13 M3v5SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYC2Om9qUUN3ME2wMlQ6PjZzIN88US=> NHHzRoZUSU6JRWK=
HC-1 M3nKN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2fDVWlEPTB;MD61NFQ4OyEQvF2= MVjTRW5ITVJ?
ACN NH\SbnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWDJR|UxRTBwNUGwNlgh|ryP NH3hUnFUSU6JRWK=
HCC1599 NYG5bWRPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX;JR|UxRTBwNUG1O{DPxE1? MU\TRW5ITVJ?
MV-4-11 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG\i[otKSzVyPUCuOVMxPDFizszN NH;keHZUSU6JRWK=
LC-2-ad M3z1Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1\UTWlEPTB;MD61N|Y3OyEQvF2= MlPpV2FPT0WU
HL-60 MlTBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlHqTWM2OD1yLkW0NlYyKM7:TR?= MV;TRW5ITVJ?
NB17 NF;jVWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlXETWM2OD1yLkW0N|gh|ryP M1XOZXNCVkeHUh?=
TE-1 NX;USoI1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkPZTWM2OD1yLkW1N|A3KM7:TR?= MVPTRW5ITVJ?
NCI-H524 M{DET2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{jOVmlEPTB;MD61OVQxOSEQvF2= MkjSV2FPT0WU
MZ7-mel M4LNTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoDkTWM2OD1yLkW2NVA2KM7:TR?= NFjpXHJUSU6JRWK=
L-363 M4DuWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF\GXllKSzVyPUCuOVY3PTdizszN NIPYUpVUSU6JRWK=
BL-41 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml;uTWM2OD1yLkW2PFg6KM7:TR?= NFHiR4ZUSU6JRWK=
LU-134-A MmTkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYTvdXdGUUN3ME2wMlU4ODd|IN88US=> NY\n[GxmW0GQR1XS
SIG-M5 NXnpeppQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{T5emlEPTB;MD61O|g1QCEQvF2= MnXwV2FPT0WU
ONS-76 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVXlbHpCUUN3ME2wMlU5OjR{IN88US=> MmW5V2FPT0WU
KARPAS-299 M1LX[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Moe2TWM2OD1yLkW4OVA1KM7:TR?= M2rY[XNCVkeHUh?=
DU-4475 M1PSVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY\JR|UxRTBwNUi3NFMh|ryP NWPZXpg1W0GQR1XS
NB69 MofWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnrxTWM2OD1yLkW5PFI2KM7:TR?= Mnu4V2FPT0WU
MHH-PREB-1 M1rrcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3K5OWlEPTB;MD62NFcyQSEQvF2= MVnTRW5ITVJ?
LU-165 Mm[4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUXpe|I2UUN3ME2wMlYyQDF{IN88US=> NGHVXFlUSU6JRWK=
LOUCY M{DQV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2HXTGlEPTB;MD62N|M3PCEQvF2= MYPTRW5ITVJ?
NCI-H526 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVfJR|UxRTBwNkO1OFEh|ryP MkHnV2FPT0WU
KE-37 Ml;1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX3weWhGUUN3ME2wMlY1Ojd4IN88US=> MX\TRW5ITVJ?
NALM-6 NUHqRlMzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGnWNWVKSzVyPUCuOlQ5PiEQvF2= NWDiSHlPW0GQR1XS
CW-2 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4\5[GlEPTB;MD62OVc6PCEQvF2= MVzTRW5ITVJ?
SU-DHL-1 M3rZe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYDqO4hKUUN3ME2wMlY2QTR5IN88US=> MXvTRW5ITVJ?
NB13 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MULJR|UxRTBwNk[4NVch|ryP NUnXdVVYW0GQR1XS
QIMR-WIL NHrqUo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWDzXHBVUUN3ME2wMlY5OzR|IN88US=> MnL6V2FPT0WU
ECC12 NWjzWFZMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4n1dGlEPTB;MD63NFA5PiEQvF2= M1ixT3NCVkeHUh?=
KALS-1 NWDaNlF3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG\BXldKSzVyPUCuO|A1QTJizszN MX;TRW5ITVJ?
COR-L279 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXTOWZM{UUN3ME2wMlcxQTl4IN88US=> NE[y[GhUSU6JRWK=
NB14 NVHwRYpCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX;sN|QzUUN3ME2wMlczPjF5IN88US=> NUDUUmczW0GQR1XS
CCRF-CEM M1rKfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVzo[JlMUUN3ME2wMlc1PjZzIN88US=> M1naVXNCVkeHUh?=
SW954 NX[1RlJnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH\pSHdKSzVyPUCuO|U6QTlizszN MWjTRW5ITVJ?
IST-SL1 NVf5NnhtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmjGTWM2OD1yLke3N|Q5KM7:TR?= M{fPWnNCVkeHUh?=
LAMA-84 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4LjN2lEPTB;MD63O|U3PyEQvF2= MmP3V2FPT0WU
Daudi NGHnPXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWHT[4t7UUN3ME2wMlc4PjhzIN88US=> NVHrb4NmW0GQR1XS
BC-3 M3:xZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV\JR|UxRTBwN{izNFgh|ryP MXTTRW5ITVJ?
HCC2998 NEnoTI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYDJR|UxRTBwN{izOkDPxE1? NXHFblhQW0GQR1XS
NCI-H69 NXyxT4xYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYfV[XpJUUN3ME2wMlgxOTR5IN88US=> MXLTRW5ITVJ?
CPC-N NX\FSIJvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUDGVYpGUUN3ME2wMlgxPTJ2IN88US=> MXfTRW5ITVJ?
NOMO-1 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYPUdnl4UUN3ME2wMlgyODh2IN88US=> NUW1U5R6W0GQR1XS
CESS NULuV5E5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4nyfmlEPTB;MD64NVE6PyEQvF2= NIjuUWdUSU6JRWK=
LC4-1 M2nFSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1HwSmlEPTB;MD64OFAxPyEQvF2= M4OxfHNCVkeHUh?=
BL-70 NYXLOY5ET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M37TVWlEPTB;MD64OVcxOiEQvF2= MkXFV2FPT0WU
ES4 NYDpd21YT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHnWU5VKSzVyPUCuPFU5PjhizszN NUS4SoFSW0GQR1XS
HCE-T MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEjodVRKSzVyPUCuPFcyPzFizszN MmD3V2FPT0WU
JAR M1PXVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEHYRoFKSzVyPUCuPFc5OjdizszN M{nWN3NCVkeHUh?=
ST486 M3jM[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIDhTVFKSzVyPUCuPFc6OTdizszN MWrTRW5ITVJ?
KS-1 NXXSSmN[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkLRTWM2OD1yLki4NFk3KM7:TR?= MXnTRW5ITVJ?
GDM-1 Mm[2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M121RWlEPTB;MD64PFY5PyEQvF2= NWTSZZVsW0GQR1XS
EHEB Mk\aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mmi5TWM2OD1yLkmyOVg2KM7:TR?= M2jod3NCVkeHUh?=
LB2518-MEL MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFPMUFRKSzVyPUCuPVMzQDRizszN Mlu2V2FPT0WU
GOTO MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWPZUWlIUUN3ME2wMlk2ODd4IN88US=> MoHYV2FPT0WU
LXF-289 NVjldW1PT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXfXOmp4UUN3ME2wMlk2QTBzIN88US=> MoX4V2FPT0WU
ES6 NXHsWXh1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXXJR|UxRTBwOU[0N|ch|ryP NI\ESIJUSU6JRWK=
OS-RC-2 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MY\JR|UxRTBwOU[4N{DPxE1? MnTYV2FPT0WU
DMS-153 NWTQe2Z5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVLJR|UxRTBwOUe0Olkh|ryP NFXNVoFUSU6JRWK=
SK-PN-DW MoLBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1nwXWlEPTB;MD65O|g{OSEQvF2= MoXOV2FPT0WU
HH MlfWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUDJR|UxRTBwOUi5OVkh|ryP MUTTRW5ITVJ?
SH-4 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGTlO|NKSzVyPUGuNFI1OSEQvF2= NGXsN|FUSU6JRWK=
MOLT-4 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF72W2xKSzVyPUGuNFM1PTRizszN MVfTRW5ITVJ?
TGW NF;FPWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF;jV3JKSzVyPUGuNFc3PzVizszN M1TWe3NCVkeHUh?=
L-540 MojxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWf4[2ZpUUN3ME2xMlExPjB2IN88US=> MkXVV2FPT0WU
PF-382 MmC4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUe2eldkUUN3ME2xMlEyPTF|IN88US=> NUTEdJhKW0GQR1XS
LC-1F MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3O5fmlEPTB;MT6xNlAxPyEQvF2= NXHEeW0zW0GQR1XS
OVCAR-4 MmTTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFfn[JBKSzVyPUGuNVMyPjVizszN MX3TRW5ITVJ?
A4-Fuk NVPFZ212T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk\5TWM2OD1zLkG1N|Y1KM7:TR?= MoHXV2FPT0WU
HCC2218 M3vP[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmTxTWM2OD1zLkG2OlQyKM7:TR?= NF7xXoJUSU6JRWK=
HAL-01 M{nqbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFrUTZdKSzVyPUGuNVY6PDNizszN NFLL[ldUSU6JRWK=
IST-MEL1 NUfMWWNQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXPnN|luUUN3ME2xMlE4PjV7IN88US=> M3LrZnNCVkeHUh?=
NCI-H719 NFSwUnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWXJR|UxRTFwMUe4PVgh|ryP MUjTRW5ITVJ?
EVSA-T MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoL1TWM2OD1zLkG4NVE1KM7:TR?= M4fOUHNCVkeHUh?=
SK-NEP-1 MnLoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF3SdWJKSzVyPUGuNlAzPjZizszN NYDoUFJ7W0GQR1XS
OCUB-M MlznS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3n0[WlEPTB;MT6yNVQ5QSEQvF2= NX;xOGhLW0GQR1XS
MEG-01 MkfOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVTJR|UxRTFwMkKxNVgh|ryP M{PrSHNCVkeHUh?=
no-10 MmH1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRTFwMkOxNVIh|ryP NEf4N3NUSU6JRWK=
MHH-CALL-2 NFewfI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIX4VZlKSzVyPUGuNlQ4OjFizszN MYHTRW5ITVJ?
SK-N-DZ MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlXaTWM2OD1zLkK0O|c3KM7:TR?= M2G3RXNCVkeHUh?=
SCLC-21H NV\CZVd[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX;JR|UxRTFwMk[0O|gh|ryP NVnnbZdqW0GQR1XS
CTV-1 MkPQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFHNfVdKSzVyPUGuNlc1OjVizszN NG[xSJJUSU6JRWK=
NB1 NVOydmcxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHL5VJNKSzVyPUGuNlc4OzJizszN M3jPbXNCVkeHUh?=
NCI-H64 NIPDNI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmHnTWM2OD1zLkK4OFYzKM7:TR?= NX6zSGx5W0GQR1XS
MDA-MB-134-VI MmTWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnSxTWM2OD1zLkK4OVc4KM7:TR?= NIr6ZZZUSU6JRWK=
LB2241-RCC M{L6TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYDJR|UxRTFwMki2OlMh|ryP NF;PfHlUSU6JRWK=
8-MG-BA NF;S[mxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVrJR|UxRTFwMki4OlYh|ryP NEfifXVUSU6JRWK=
LP-1 M1;yVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY\JR|UxRTFwMkm5OFch|ryP MWLTRW5ITVJ?
LS-411N MkfCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRTFwM{C5PVgh|ryP NIjLeYFUSU6JRWK=
CAL-148 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX;lT2xUUUN3ME2xMlMzPTR{IN88US=> M2W5OnNCVkeHUh?=
NCI-H2171 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX76cFdTUUN3ME2xMlM1PTB{IN88US=> NH3IdnVUSU6JRWK=
JiyoyeP-2003 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnK3TWM2OD1zLkO1N|kh|ryP NWrvS4FvW0GQR1XS
NCI-H2107 NEXENHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mo\PTWM2OD1zLkO1PFg{KM7:TR?= NWPnTI9sW0GQR1XS
BB30-HNC NFy1VIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV;0O2RiUUN3ME2xMlM5QTd6IN88US=> NIPVOolUSU6JRWK=
K-562 NYPSSHBTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYPJR|UxRTFwM{myNVkh|ryP MU\TRW5ITVJ?
PSN1 NXfJNZJMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{nH[WlEPTB;MT60NlI5PyEQvF2= MVPTRW5ITVJ?
HCC2157 NWrFXGRST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWLJR|UxRTFwNEK2PVEh|ryP NVO3UIlxW0GQR1XS
SBC-1 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVPJR|UxRTFwNEK3OFEh|ryP NHrGeHJUSU6JRWK=
MC116 M3LORWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH[5W5pKSzVyPUGuOFM3OTVizszN NEG4co5USU6JRWK=
KARPAS-422 MnHsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVzJR|UxRTFwNEWzOVgh|ryP NUjqTIkxW0GQR1XS
LB996-RCC MmKzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnjPTWM2OD1zLkS3NVA{KM7:TR?= MkHwV2FPT0WU
MSTO-211H NILWUYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYXFOXR7UUN3ME2xMlQ4QTh5IN88US=> NVH0cploW0GQR1XS
BT-474 Ml;XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVvJR|UxRTFwNUG3OlQh|ryP MWDTRW5ITVJ?
A388 NHHGVHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEO2b2lKSzVyPUGuOVE6PDVizszN NFuxSItUSU6JRWK=
SJSA-1 NF;5[XVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV\lSmxtUUN3ME2xMlUzOjZizszN MYfTRW5ITVJ?
COLO-829 NXjlRplqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEKxe4hKSzVyPUGuOVM2PjRizszN NGDBeFlUSU6JRWK=
KM-H2 NGjXTVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVXmTW43UUN3ME2xMlU3PjdizszN MoP1V2FPT0WU
GR-ST MlnwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXL2R5U6UUN3ME2xMlU3QDJizszN MorVV2FPT0WU
RPMI-8866 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXG3UYV[UUN3ME2xMlYxOTR2IN88US=> MVTTRW5ITVJ?
KG-1 NIH3XGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUHpSZVuUUN3ME2xMlYyQTBzIN88US=> Mn[yV2FPT0WU
NCI-H82 M{\ITWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF\6fHNKSzVyPUGuOlM1ODZizszN NIjVUWpUSU6JRWK=
LB1047-RCC MnfqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXnJR|UxRTFwNkO0OVkh|ryP Mnr2V2FPT0WU
KM12 NFi0cJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1vzXWlEPTB;MT62OFch|ryP NU\KSYdKW0GQR1XS
NB5 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlGyTWM2OD1zLk[1Olc4KM7:TR?= NW\ZdZVrW0GQR1XS
HDLM-2 NGHKN4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUXJR|UxRTFwNkiyPFEh|ryP NGnwdo9USU6JRWK=
KU812 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFHaV3JKSzVyPUGuOlk3ODVizszN MkG3V2FPT0WU
DB NFnifodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MofyTWM2OD1zLkewN|U{KM7:TR?= MmPxV2FPT0WU
HD-MY-Z MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3nkXGlEPTB;MT63OVI{PCEQvF2= NXP0enVNW0GQR1XS
KURAMOCHI M1L1O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYHJR|UxRTFwN{eyNFch|ryP MUfTRW5ITVJ?
ETK-1 NIfrVXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVrkcIpSUUN3ME2xMlc5QDd7IN88US=> MmPIV2FPT0WU
SK-UT-1 NVvJe|E1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGPuXGJKSzVyPUGuO|k{QDhizszN NHPpSm1USU6JRWK=
HUTU-80 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3jPfWlEPTB;MT63PVUxQCEQvF2= NGT6ZpRUSU6JRWK=
ES7 Mkf2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX7JR|UxRTFwOECzNFIh|ryP NYP4fXl1W0GQR1XS
SW872 MkLSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NILpVoJKSzVyPUGuPFE{QTVizszN NXTUPXdOW0GQR1XS
TK10 MlXGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4TtXWlEPTB;MT64N|ExQCEQvF2= MX7TRW5ITVJ?
LB831-BLC MnK5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXXJR|UxRTFwOEO1OlMh|ryP NWnrOJcyW0GQR1XS
TE-9 M1XLXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVfJR|UxRTFwOES0NlIh|ryP MV;TRW5ITVJ?
MLMA MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEPCSppKSzVyPUGuPFgzOzRizszN NVe0[JJGW0GQR1XS
D-542MG M4XoVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWKyO4ZxUUN3ME2xMlg6Ozd|IN88US=> NH:0O3BUSU6JRWK=
EW-16 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVvXOlBkUUN3ME2xMlkzPzJizszN MkTKV2FPT0WU
LOXIMVI MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH65TXVKSzVyPUGuPVMzQCEQvF2= MV3TRW5ITVJ?
GB-1 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXTJR|UxRTFwOUO4OlYh|ryP M2PGTnNCVkeHUh?=
IST-SL2 NVrpbnhZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2PLbWlEPTB;Mj6wNFI3OiEQvF2= Mn7rV2FPT0WU
LAN-6 NHjNcXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3LUTGlEPTB;Mj6wNVk3PiEQvF2= NVzV[nBvW0GQR1XS
NCI-H510A M1flUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlvlTWM2OD1{LkC0OVAzKM7:TR?= M{DOV3NCVkeHUh?=
NCI-H1092 MojGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXXPOYpIUUN3ME2yMlA2OTJ2IN88US=> NV7u[pd{W0GQR1XS
HT NWjrS21WT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnuwTWM2OD1{LkGwOFU1KM7:TR?= M1nUfXNCVkeHUh?=
RL95-2 M2nmbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWDJRnNwUUN3ME2yMlEyPDh{IN88US=> NYW4TpE5W0GQR1XS
NCI-H1355 NG\5cJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGPKNIlKSzVyPUKuNVE4QTJizszN NV7q[JVPW0GQR1XS
NCI-H720 NXywNGZYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXjJR|UxRTJwMU[4O|Mh|ryP MWfTRW5ITVJ?
NCI-H1522 NEfv[5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1O4SWlEPTB;Mj6yNVczOyEQvF2= MXnTRW5ITVJ?
LB373-MEL-D MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWDJR|UxRTJwMk[5NFIh|ryP NVLWdpZiW0GQR1XS
DG-75 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXjJR|UxRTJwMkexOFgh|ryP M{PFb3NCVkeHUh?=
ML-2 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEX1[2FKSzVyPUKuN|I5PTVizszN MkLBV2FPT0WU
SF126 NGfm[VdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mmj5TWM2OD1{LkOzNFk1KM7:TR?= MUDTRW5ITVJ?
MPP-89 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2PhdmlEPTB;Mj6zN|E1PSEQvF2= Mnv4V2FPT0WU
NCI-H345 NEjqUlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIrIWodKSzVyPUKuN|MzPzdizszN M{LoTXNCVkeHUh?=
LS-123 NV3MUFYyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWq4Tm5DUUN3ME2yMlM1QTN4IN88US=> M2\RU3NCVkeHUh?=
NB10 NGDTPZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1z4OWlEPTB;Mj60NVA6OiEQvF2= MXvTRW5ITVJ?
CGTH-W-1 NXKyUHdPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWHCbXZRUUN3ME2yMlQzOjZ5IN88US=> MV3TRW5ITVJ?
CP66-MEL NYjHU2FoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUTJR|UxRTJwNEe3O{DPxE1? M2XxWnNCVkeHUh?=
L-428 MnvUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MorWTWM2OD1{LkS4OVIyKM7:TR?= M4\k[HNCVkeHUh?=
DMS-79 M1PnPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVX3cmxOUUN3ME2yMlU1OTB|IN88US=> M3;WdXNCVkeHUh?=
NCI-H1882 MoLhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUnJR|UxRTJwNke1OlIh|ryP NXHEfZRsW0GQR1XS
KGN M1vjNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXjJR|UxRTJwN{[4O|Yh|ryP MkHkV2FPT0WU
EW-1 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHjGU5NKSzVyPUKuO|cxQDNizszN NE\CbVVUSU6JRWK=
U-266 M3\3bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{HEcGlEPTB;Mj64OFgzOyEQvF2= NVPHTZZpW0GQR1XS
COLO-320-HSR Ml7sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUDyWoRnUUN3ME2yMlg2PjRzIN88US=> NV\yR3VLW0GQR1XS
KMOE-2 M3HjZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUfMb2F1UUN3ME2yMlg4PzFzIN88US=> MYfTRW5ITVJ?
BB49-HNC NUHkSHdqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnXHTWM2OD1{LkmyOFgh|ryP NIHB[plUSU6JRWK=
GI-1 NXzmUm5JT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVzBXlc1UUN3ME2yMlkzQTV5IN88US=> MnjnV2FPT0WU
NCI-H1304 M1S5dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFTmcWZKSzVyPUOuNFA2OTFizszN MU\TRW5ITVJ?
NCI-H2227 NFTNWI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXfYUmV3UUN3ME2zMlAzODd7IN88US=> Mni4V2FPT0WU
U-87-MG MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnTrTWM2OD1|LkCzOVE{KM7:TR?= NF;BS2JUSU6JRWK=
NCI-H747 NG\lVVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NILa[5dKSzVyPUOuNFUzODZizszN MVrTRW5ITVJ?
CTB-1 MkXuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUK1U3hTUUN3ME2zMlA2Ozd4IN88US=> Mne3V2FPT0WU
RPMI-8226 M4\PW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYfJR|UxRTNwMUSzO|gh|ryP NGLXSm1USU6JRWK=
NCI-H2141 Mmr0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH[4VGtKSzVyPUOuNVY2PjZizszN MkLhV2FPT0WU
IST-MES1 NWG4bIFyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEjURpNKSzVyPUOuNVgzPzlizszN MnOwV2FPT0WU
TE-5 M{O0XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEXnUHlKSzVyPUOuNlE{PDJizszN NITDU4VUSU6JRWK=
UACC-257 NF32epBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXn3[Zg{UUN3ME2zMlQ{PjV7IN88US=> NHriRmFUSU6JRWK=
SK-N-FI MlPRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MU\JR|UxRTNwNEWyNlch|ryP M2XQZnNCVkeHUh?=
MFH-ino M{nwPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUPJR|UxRTNwNE[1PFkh|ryP NEGyfXNUSU6JRWK=
SF268 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYr5T|lQUUN3ME2zMlQ5OTd2IN88US=> NV24[5R1W0GQR1XS
TE-12 NUPNdYE4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWrlPZdmUUN3ME2zMlUyPjl7IN88US=> M3rRUnNCVkeHUh?=
NB6 MnXiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV3HRZVHUUN3ME2zMlU2PTZ|IN88US=> M2\ROXNCVkeHUh?=
DJM-1 MmHVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVLJR|UxRTNwNUm4PVkh|ryP NGHQfnhUSU6JRWK=
MZ1-PC MnjxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1zNdGlEPTB;Mz62NVYzPCEQvF2= NUDUZY5uW0GQR1XS
OCI-AML2 MljjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVnaWZozUUN3ME2zMlYzPjdzIN88US=> NULMem1NW0GQR1XS
NCI-H1155 Mny2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYfsXnppUUN3ME2zMlcxQTR5IN88US=> M3r1eXNCVkeHUh?=
RKO NXq4WpFMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4nsT2lEPTB;Mz63O|E5QSEQvF2= MXPTRW5ITVJ?
ECC4 M2[5Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUL5V2tLUUN3ME2zMlk4OTl3IN88US=> Mm\EV2FPT0WU
BB65-RCC NX7VdnpGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHjFWGRKSzVyPUOuPVc2PDdizszN MUjTRW5ITVJ?
EB-3 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVu5XVR6UUN3ME2zMlk6PjN|IN88US=> MXnTRW5ITVJ?
SHP-77 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2n5T2lEPTB;ND6wNFUzPCEQvF2= M2K5fnNCVkeHUh?=
NCI-H2196 NEPld3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2LiXmlEPTB;ND6wOVYzPSEQvF2= MVLTRW5ITVJ?
GI-ME-N M3rkbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWC2XVJ4UUN3ME20MlA3Ozl7IN88US=> MoLJV2FPT0WU
MN-60 NIOzUndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4n0WWlEPTB;ND6xNFg4KM7:TR?= MlPpV2FPT0WU
NCI-H1694 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYHJR|UxRTRwMUO0NFUh|ryP NF;MOVJUSU6JRWK=
LU-65 M{fxb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUHJR|UxRTRwMUWzN|Ih|ryP M3vTc3NCVkeHUh?=
NCI-H1436 NILifpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3PmTGlEPTB;ND6xPFM{OyEQvF2= M3nJOHNCVkeHUh?=
KINGS-1 NWHQOopHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEj5bXhKSzVyPUSuN|E1OzJizszN NV\sdlFZW0GQR1XS
GT3TKB MoPHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;XR2szUUN3ME20MlM{OjZ6IN88US=> Ml32V2FPT0WU
Becker NYLOT417T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEDocWpKSzVyPUSuN|c{OTJizszN NIfQZpRUSU6JRWK=
HCC1187 MmPBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYPOS4loUUN3ME20Mlg6PjV5IN88US=> MYnTRW5ITVJ?
D-502MG NIq2XYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGLMS2VKSzVyPUWuNFA1OTZizszN NWnod2pUW0GQR1XS
VA-ES-BJ M{TBOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYXyWIR2UUN3ME21MlE{Pzd6IN88US=> M3T0WHNCVkeHUh?=
NB7 NUHvXGRyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEjtOldKSzVyPUWuNVQyOTJizszN MWDTRW5ITVJ?
SW962 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYfJR|UxRTVwM{i4NVQh|ryP MmG3V2FPT0WU
no-11 MnXaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnf4TWM2OD13Lke2N|Q{KM7:TR?= Ml7FV2FPT0WU
KNS-81-FD MkThS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVjJR|UxRTVwOUC2PVQh|ryP MWrTRW5ITVJ?
COLO-684 NILQN5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVLJR|UxRTVwOUm0PVQh|ryP M1LxUnNCVkeHUh?=
D-263MG NVHrTI9rT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3OzWGlEPTB;Nj6wPFg6PSEQvF2= M3Tie3NCVkeHUh?=
EW-24 NIP5W2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVvPRnp4UUN3ME22MlI5PTFizszN M1n1S3NCVkeHUh?=
TE-10 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFTqbGxKSzVyPU[uOFI3OjNizszN M4TYTHNCVkeHUh?=
EKVX Moq5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1SxO2lEPTB;Nj60OlMzOSEQvF2= M{jJOnNCVkeHUh?=
NCI-H1648 NIXCWIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3SwOWlEPTB;Nj62O|U2PyEQvF2= MnfHV2FPT0WU
LB771-HNC NWXL[FNNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXTJe|J1UUN3ME22MlkzOzBzIN88US=> NWn3WllNW0GQR1XS
SK-MEL-1 M1rXeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnOxTWM2OD16LkGzNVY3KM7:TR?= NX7RUJNQW0GQR1XS
COLO-668 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmnWTWM2OD16LkK3O|g3KM7:TR?= NFzkRplUSU6JRWK=
EW-12 NVfDWHlXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEHpc2RKSzVyPUiuOFA5ODNizszN NYSxW4pQW0GQR1XS
A253 NITJbWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFvpS2RKSzVyPUiuPFQ3PjFizszN MmmyV2FPT0WU
NCI-H2126 MlzpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVPiTo9yUUN3ME24Mlg6OzF7IN88US=> NI\EOnpUSU6JRWK=
Calu-6 Mn;RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVLJR|UxRThwOUmwOFIh|ryP M2PjSnNCVkeHUh?=
NCI-H23 MmfQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYrJR|UxRTlwMUe3OFYh|ryP MV7TRW5ITVJ?
WSU-NHL MlHpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVTmNmZJUUN3ME25Mlc4PDd6IN88US=> NG\FdIdUSU6JRWK=
MMAC-SF MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYjJR|UxRTlwOUe5NFQh|ryP NXP0T4Z1W0GQR1XS
SK-LMS-1 NH3DNFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWnjPZdLUUN3ME2xNE4zQDN2IN88US=> MnjKV2FPT0WU
GCIY MmTZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG\UTlhKSzVyPUGwMlU6OjRizszN NEHZ[HRUSU6JRWK=
TE-15 MnfLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXjJR|UxRTFzLk[wNFQh|ryP Mlm2V2FPT0WU
EoL-1-cell MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV;JR|UxRTFzLke2PFIh|ryP M{[2N3NCVkeHUh?=
NCI-H2081 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUnJR|UxRTFzLke3PFYh|ryP NWjhTJZYW0GQR1XS
EW-3 Ml\5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlLaTWM2OD1zMj6yOFY{KM7:TR?= M3\PUXNCVkeHUh?=
CAS-1 Ml;sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mli2TWM2OD1zMj6zOlMyKM7:TR?= MUDTRW5ITVJ?
C2BBe1 M3[zV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUnJR|UxRTF{Lk[xN|Eh|ryP MkTHV2FPT0WU
D-247MG Mln6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXjJR|UxRTF{Lke5OVIh|ryP Mkf4V2FPT0WU
NCI-SNU-5 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3nheWlEPTB;MUKuPFAyOyEQvF2= MUPTRW5ITVJ?
LS-1034 M2G5ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIT1N4RKSzVyPUG0MlM6PzVizszN MmPvV2FPT0WU
EW-18 NEjaSnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYqwNHhSUUN3ME2xOE41PDhizszN MnfZV2FPT0WU
Raji M3;ReWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX7UOXU4UUN3ME2xOE42ODR7IN88US=> MkPMV2FPT0WU
D-283MED NIDYNpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVHJR|UxRTF2Lk[yO|Eh|ryP M1j0cnNCVkeHUh?=
MZ2-MEL MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWTJR|UxRTF2Lkm2PVYh|ryP MkHsV2FPT0WU
NCI-SNU-16 NHLlT4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWrJR|UxRTF3LkS2N|Mh|ryP NV:5V4dnW0GQR1XS
P30-OHK NF7UbZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXjUSWxZUUN3ME2xO{44QDNzIN88US=> NIrKenRUSU6JRWK=
RXF393 NFjzeVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1jOdGlEPTB;MUmuNFE5PiEQvF2= NGPzU3ZUSU6JRWK=
NCI-H1395 NEDpVIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXPJR|UxRTJyLk[3NFMh|ryP NH\0XpRUSU6JRWK=
U-698-M M1zhb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{HCbWlEPTB;MkCuO|A4PSEQvF2= M3vISXNCVkeHUh?=
NCI-SNU-1 NVnUb2ZMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn7rTWM2OD1{MD63NlI{KM7:TR?= NV3pNVRKW0GQR1XS
SW684 NVPMTGFnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFL3PHNKSzVyPUKxMlE4OTZizszN M2L1THNCVkeHUh?=
NCI-H716 M4LVd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVuxWIszUUN3ME2yNU4{OTV2IN88US=> NVywUodkW0GQR1XS
JVM-2 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUjJR|UxRTJzLkSxN|Mh|ryP M3XPfHNCVkeHUh?=
NCI-H1581 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGTtSFlKSzVyPUKyMlQyPDhizszN NE\SWmxUSU6JRWK=
CA46 NFTNW5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUjjZXJEUUN3ME2zNU43QTN4IN88US=> NXr5UFVMW0GQR1XS
SNB75 M1PUVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MW\JR|UxRTN|Lk[1NFMh|ryP M2PzeHNCVkeHUh?=
KNS-42 NW\QWnhkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{\IXWlEPTB;M{WuPVYzPCEQvF2= MorXV2FPT0WU
TUR NGfUW5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUTJR|UxRTN4LkC1NlEh|ryP NEXnZ2FUSU6JRWK=
REH MmrRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlWyTWM2OD1|Nz64NlEyKM7:TR?= M2fRZ3NCVkeHUh?=
EW-22 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml\YTWM2OD12Mj6yPFg2KM7:TR?= M4G4V3NCVkeHUh?=
NCI-H446 M4LWdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{DOWmlEPTB;NEKuO|g2OyEQvF2= MYnTRW5ITVJ?
ES3 NHTofJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkPqTWM2OD12Mz6xN|M6KM7:TR?= MYXTRW5ITVJ?
EW-11 M3\4NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUnJR|UxRTR2LkiyNVgh|ryP NGDa[4xUSU6JRWK=
RH-1 MoqzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn\uTWM2OD12Nz61PFEzKM7:TR?= MX7TRW5ITVJ?

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
AcH3 / AcH4 / HDAC1 / HDAC2 / HDAC3; 

PubMed: 24203492     


HCT-15 or fresh primary NK cells were treated with entinostat for 24 h, and AcH3, AcH4, and HDAC1, 2, and 3 were detected by Western blotting. 

Cleaved PARP; 

PubMed: 19148581     


Induction of PARP cleavage in Daoy cells upon exposure to MS-275 was demonstrated by Western blot analyses using antibodies that recognize the cleaved 89 kDa PARP protein. Pan-Actin (45 kDa) was used as a loading control.

Caspase 8 ; 

PubMed: 19148581     


Cleavage of pro-Caspase-8 was demonstrated by Western blotting with extracts prepared from Daoy cells treated with 2.5 µM MS-275 for various time periods. Antibodies specific to human Caspase-8 or the loading control, pan-Actin were used to probe protein expression.

DR4 / DR5; 

PubMed: 19148581     


Western blotting to detect DR4 and DR5 expression upon treatment of Daoy cells with 2.5 µM MS-275 for 4, 8 and 24 h.

TopoIIα / TopoIIβ; 

PubMed: 21254166     


Upper panel, concentration-dependent effects of AR42, MS-275 and vorinostat on the expression of topoIIα versus topoIIβ after 48 h. Lower panel, time-dependent effect of 0.5 μM AR42 and 5 μM MS-275 on topoIIα versus topoIIβ expression in PLC-5 cells.

24203492 19148581 21254166
Immunofluorescence
phalloidin / snail; 

PubMed: 29855565     


(C) Effect of MS-275 treatment on Snail expression and localization. MCs (mesothelial cells) were treated with MS-275 (250 nM), or DMSO for 48 hr and then stimulated with TGFβ1 (2 ng/ml) for 24 h before processing for immunofluorescence with a monoclonal antibody against Snail. Cell nuclei are shown in blue (Hoechst 33342). Confocal images are shown from one representative experiment of three performed.

DR4 / DR5; 

PubMed: 19148581     


Flow Cytometry to measure cell surface expression of FAS, DR4 and DR5 using PE-labeled antibodies. Cells stained with isotype matched anti-human IgG antibodies served as controls.

H3K4Me3 / H3K9Me3; 

PubMed: 22468166     


Immunocytochemical analysis of the effects of AR42, SAHA, and MS-275 at the indicated concentrations on H3K4Me3 (upper panels) and H3K9Me3 (lower panels) after 24 h of treatment in LNCaP cells.

29855565 19148581 22468166
Growth inhibition assay
Cell proliferation; 

PubMed: 24203492     


(A) HCT-15 cells were cultured in indicated concentrations of entinostat for up to 72 h, and proliferation determined by MTT assay as indicated. (B) HCT-15, CCH-OS-D, COL and HOS cells were cultured in indicated concentrations of entinostat for 72 h, and viable cell number was determined using the Vi-cell assay and proliferation index calculated. (C) Freshly-isolated human NK cells were cultured in indicated concentrations of entinostat for up to 72 h, and viability was assessed by flow cytometry for 7-AAD uptake. *, P < 0.05, **; P ≤ 0.01; ***, P ≤ 0.001

Cell viability; 

PubMed: 28969017     


PANC-1, MIA PaCa-2, BxPC3, CFPAC-1, SUIT2 and SUIT2 Clone 1 cells were plated at a density of 3-5×103 per well in 96-well microtiter plates, allowed to adhere overnight and incubated for 72 hours in the presence of variable concentrations of entinostat (0-100μM). Cell viability was determined by XTT assays. The data presented are the mean values from triplicate wells from two independent experiments ±SE.

24203492 28969017
ELISA
GCP-2 / MCP-2 / MIF ; 

PubMed: 24241152     


MS-275 and SAHA suppressed the secretion of GCP-2, MCP-2 and MIF in E11 cells. (A) GCP suppression. (B) MCP-2 suppression. (C) MIF suppression. E11 cells were incubated with HDAC inhibitors at various concentrations for 1 h before they were stimulated by LPS. 24 h later, the secretion of GCP-2, MCP-2 and MIF were quantified by ELISA (n = 8). Bars show the mean and SD in (A–C).

24241152
In vivo MS-275 exhibits great antitumor activity against human tumor xenografts except HCT-15 at 49 mg/kg. [1] MS-275 demonstrates promising therapeutic potential in both solid and hematologic malignancies, as well as regulation of physiologic and aberrant gene expression. [4] MS-275, combination with IL-2, has great antitumor activity to renal cell carcinoma xenograft model, which due to decreased T regulatory cells and increased splenocytes. [5]

Protocol

Kinase Assay:

[6]

+ Expand

Standard HDAC Assays:

Rat liver enzyme is diluted 1:6 with HDAC buffer. Recombinant human HDACs are diluted 1:4 in HDAC buffer. For standard HDAC assays, 60 μL of HDAC buffer is mixed with 10 μL of diluted enzyme solution at 30 °C. The HDAC reaction is started by adding 30 μL substrate solution in HDAC buffer followed by 30 min of incubation at 30 °C. The reaction is stopped by adding 100 μL trypsin solutions (10 mg/ml trypsin in 50 mM Tris-HCl [pH 8.0], 100 mM NaCl, 2 μM TSA). After a 20 min incubation period at 30 °C, the release of AMC is monitored by measuring the fluorescence at 460 nm (λex = 390 nm). Fluorescence intensity is calibrated using free AMC. For standard time course experiments, 20 pmol of substrate is used in the initial 100 μL HDAC reaction. Km and Vmax values are determined by measuring the fluorescence AMC generated by enzymatic cleavage of 2–50 pmol of substrate. The experimental data are analyzed using a Hanes plot. The AMC signals are recorded against a blank with buffer and substrate but without the enzyme.
Cell Research:

[2]

+ Expand
  • Cell lines: A2780, Calu-3, HL-60, K562, St-4, HT-29, KB-3-1, Capan-1, 4-1St and HCT-15 cells
  • Concentrations: ~ 10 μM
  • Incubation Time: 3 days
  • Method:

    Cancer cells (5 × 103) are seeded into each well of 96-well plates and cultured with graded concentrations of MS-275 for 3 days. The cells are stained with 0.1 mg/mL neutral red for 1 hour in a CO2-incubator, and, after aspiration of the medium, OD540 of the neutral red solubilized with 50 μL of ethanol and 150 μL of 0.1 M Na2HPO4 is measured. The IC50 value is determined by plotting growth inhibition of the cells against the logarithm of the drug concentration.


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: A2780, HT-29, HTC-15, KB-3-1, 4-1St, St-4, Capan-1 and Calu-3 cells are injected subcutaneously into the flank of nude mice.
  • Formulation: Dissolved with 0.05 N HCl, 0.1% Tween 80
  • Dosages: 12.3, 24.5 and 49 mg/kg
  • Administration: Administered orally once daily 5 days per week for 4 weeks
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 75 mg/mL (199.25 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+30% PEG 300+ddH2O
For best results, use promptly after mixing.
10mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 376.41
Formula

C21H20N4O3

CAS No. 209783-80-2
Storage powder
in solvent
Synonyms SNDX-275

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03829930 Recruiting Drug: Entinostat|Drug: Enzalutamide Prostate Adenocarcinoma George Washington University May 1 2019 Phase 1
NCT03765229 Recruiting Drug: Entinostat|Drug: Pembrolizumab Melanoma UNC Lineberger Comprehensive Cancer Center|Syndax Pharmaceuticals Inc. March 22 2019 Phase 2
NCT03473639 Recruiting Drug: Entinostat|Drug: Capecitabine Metastatic Breast Cancer|Breast Cancer University of Virginia|Syndax Pharmaceuticals January 29 2019 Phase 1
NCT03361800 Recruiting Drug: Entinostat Breast Cancer|Invasive Breast Cancer|ER-Negative PR-Negative HER2-Negative Breast Cancer UNC Lineberger Comprehensive Cancer Center|Syndax Pharmaceuticals|National Cancer Institute (NCI) November 28 2018 Early Phase 1
NCT03192111 Completed Drug: Entinostat Renal Impairment|Healthy Volunteer Syndax Pharmaceuticals July 27 2017 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I would like to use Entinostat(Catalog No.S1053) for animal study. What is your recommendation for the solvent? What is the role of PEG 300 in this case? Can I use DMSO only and dilute it with PBS or HBSS?

  • Answer:

    2%DMSO/30%PEG/68%Water is recommended. PEG is an important polymer that helps with the solubility of hydrophobic drugs. If you use DMSO only and dilute it with PBS or HBSS, Entinostat will likely to precipitate out since it has very low solubility in water.

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Related HDAC Products

Tags: buy Entinostat (MS-275) | Entinostat (MS-275) supplier | purchase Entinostat (MS-275) | Entinostat (MS-275) cost | Entinostat (MS-275) manufacturer | order Entinostat (MS-275) | Entinostat (MS-275) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID